MA43271A - Formulations améliorées de déférasirox et leurs procédés de fabrication - Google Patents
Formulations améliorées de déférasirox et leurs procédés de fabricationInfo
- Publication number
- MA43271A MA43271A MA043271A MA43271A MA43271A MA 43271 A MA43271 A MA 43271A MA 043271 A MA043271 A MA 043271A MA 43271 A MA43271 A MA 43271A MA 43271 A MA43271 A MA 43271A
- Authority
- MA
- Morocco
- Prior art keywords
- improved
- manufacturing processes
- deferasirox
- formulations
- deferasirox formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562180998P | 2015-06-17 | 2015-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43271A true MA43271A (fr) | 2018-09-26 |
Family
ID=57546755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043271A MA43271A (fr) | 2015-06-17 | 2016-06-17 | Formulations améliorées de déférasirox et leurs procédés de fabrication |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10265301B2 (enExample) |
| EP (1) | EP3310354A4 (enExample) |
| JP (1) | JP2018517734A (enExample) |
| CN (1) | CN107847490A (enExample) |
| AU (3) | AU2016280280B2 (enExample) |
| CA (1) | CA2989145C (enExample) |
| HK (1) | HK1254608A1 (enExample) |
| IL (1) | IL256322B (enExample) |
| MA (1) | MA43271A (enExample) |
| WO (1) | WO2016205658A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2565279B1 (en) | 2007-12-05 | 2014-12-03 | Complete Genomics, Inc. | Efficient base determination in sequencing reactions |
| US10098857B2 (en) | 2008-10-10 | 2018-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds |
| CN107267596A (zh) | 2009-06-15 | 2017-10-20 | 考利达基因组股份有限公司 | 用于长片段阅读测序的方法和组合物 |
| US10837879B2 (en) | 2011-11-02 | 2020-11-17 | Complete Genomics, Inc. | Treatment for stabilizing nucleic acid arrays |
| CZ2017255A3 (cs) * | 2017-05-04 | 2018-11-14 | Zentiva, K.S. | Filmem potažené tablety Deferasiroxu |
| WO2019055490A1 (en) | 2017-09-14 | 2019-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | PACKAGING OF IRRADIED FABRIC FOR FAT GREETING RETENTION |
| CN111511365A (zh) * | 2017-11-10 | 2020-08-07 | 分散技术有限责任公司 | 改进的药物制剂 |
| WO2020061474A1 (en) * | 2018-09-20 | 2020-03-26 | Tautona Group Ip Holding Company, L.L.C. | Iron chelating compounds for treating aesthetic skin conditions |
| EP4096791A1 (en) | 2020-01-31 | 2022-12-07 | Nanocopoeia LLC | Amorphous nilotinib microparticles and uses thereof |
| CA3181361A1 (en) | 2020-04-30 | 2021-11-04 | Nanocopoeia, Llc | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib |
| CN112870361A (zh) * | 2021-01-28 | 2021-06-01 | 重庆医科大学 | 铁死亡抑制剂在制备预防或治疗铁过载导致的骨质疏松或骨丢失的药物中的应用 |
| CN114994205B (zh) * | 2022-05-30 | 2023-03-28 | 上海奥科达医药科技股份有限公司 | 地拉罗司颗粒剂中相关杂质的检测方法 |
| WO2025151876A1 (en) * | 2024-01-11 | 2025-07-17 | Minneamrita Therapeutics Llc | Triptolide formulations |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0009056D0 (en) * | 2000-04-12 | 2000-05-31 | Nestle Sa | Composition comprising free amino acids |
| RU2008119410A (ru) * | 2005-10-19 | 2009-11-27 | Новартис АГ (CH) | Диспергируемые таблетки, включающие деферасирокс |
| CA2990445C (en) | 2007-08-21 | 2020-05-05 | Board Of Regents, The University Of Texas System | Thermo-kinetic mixing for pharmaceutical applications |
| EP2062572A1 (en) * | 2007-11-19 | 2009-05-27 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions |
| US20110097413A1 (en) * | 2008-04-21 | 2011-04-28 | Actavis Group Ptc Ehf | Solid state forms of deferasirox salts and process for the preparation thereof |
| JP2013512893A (ja) * | 2009-12-07 | 2013-04-18 | マピ ファーマ リミテッド | デフェラシロクスの調製方法、及びデフェラシロクスの多形体 |
| EP2590630B1 (en) * | 2010-07-08 | 2015-04-29 | ratiopharm GmbH | Oral dosage form of deferasirox |
| WO2012025935A2 (en) * | 2010-08-25 | 2012-03-01 | Ramamohan Rao Davuluri | A process for the preparation of 2-(2-hydroxyphenyl)-benz[1,3]oxazin-4-one and its use for preparation of 4-[3, 5-bis (2-hydroxyphenyl)-1h-1, 2, 4-triazol-1-yl] benzoic acid |
| BR112013007276A2 (pt) * | 2010-10-01 | 2016-06-14 | Cipla Ltd | composição farmacêutica, processo para preparar uma composição farmacêutica, uso da coposição farmacêutica e método para tratar sobrecarga crônica de ferro |
| US20140039031A1 (en) * | 2011-02-23 | 2014-02-06 | Dispersol Technologies. LLC | Pharmaceutical formulations of acetyl-11-keto-b-boswellic acid, diindolylmethane, and curcumin for pharmaceutical applications |
| SI2964202T1 (sl) * | 2013-03-08 | 2019-02-28 | Novartis Ag | Peroralne formulacije deferasiroksa |
| CN105377256A (zh) | 2013-05-10 | 2016-03-02 | 奇普拉股份有限公司 | 低剂量药物组合物 |
-
2016
- 2016-06-17 EP EP16812529.2A patent/EP3310354A4/en active Pending
- 2016-06-17 CN CN201680042313.0A patent/CN107847490A/zh active Pending
- 2016-06-17 HK HK18113574.7A patent/HK1254608A1/zh unknown
- 2016-06-17 US US15/185,888 patent/US10265301B2/en active Active
- 2016-06-17 AU AU2016280280A patent/AU2016280280B2/en active Active
- 2016-06-17 JP JP2017565048A patent/JP2018517734A/ja active Pending
- 2016-06-17 CA CA2989145A patent/CA2989145C/en active Active
- 2016-06-17 WO PCT/US2016/038089 patent/WO2016205658A1/en not_active Ceased
- 2016-06-17 MA MA043271A patent/MA43271A/fr unknown
-
2017
- 2017-06-28 US US15/636,174 patent/US10258608B2/en active Active
- 2017-12-14 IL IL256322A patent/IL256322B/en unknown
-
2019
- 2019-02-06 US US16/268,785 patent/US11878005B2/en active Active
-
2021
- 2021-12-02 AU AU2021277731A patent/AU2021277731B2/en active Active
-
2023
- 2023-11-24 US US18/518,819 patent/US20240091201A1/en active Pending
-
2024
- 2024-04-17 AU AU2024202528A patent/AU2024202528A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11878005B2 (en) | 2024-01-23 |
| CN107847490A (zh) | 2018-03-27 |
| AU2016280280A1 (en) | 2018-01-04 |
| US20170027911A1 (en) | 2017-02-02 |
| AU2021277731A1 (en) | 2021-12-23 |
| CA2989145C (en) | 2024-10-29 |
| JP2018517734A (ja) | 2018-07-05 |
| US20190167643A1 (en) | 2019-06-06 |
| EP3310354A1 (en) | 2018-04-25 |
| US20170296514A1 (en) | 2017-10-19 |
| AU2024202528A1 (en) | 2024-05-09 |
| US20240091201A1 (en) | 2024-03-21 |
| AU2021277731B2 (en) | 2024-04-11 |
| CA2989145A1 (en) | 2016-12-22 |
| WO2016205658A1 (en) | 2016-12-22 |
| HK1254608A1 (zh) | 2019-07-26 |
| US10258608B2 (en) | 2019-04-16 |
| US10265301B2 (en) | 2019-04-23 |
| IL256322A (en) | 2018-02-28 |
| AU2016280280B2 (en) | 2021-09-02 |
| EP3310354A4 (en) | 2018-12-12 |
| IL256322B (en) | 2022-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43271A (fr) | Formulations améliorées de déférasirox et leurs procédés de fabrication | |
| MA44869A (fr) | Cellules génétiquement modifiées et leurs procédés de fabrication | |
| EP3867936A4 (en) | Nano-graphitic sponges and methods for fabricating the same | |
| IL253676A0 (en) | Batch normalization layers | |
| MA48475A (fr) | Procédés de fabrication de niraparib | |
| EP3292582A4 (en) | ELECTROCHLORINATING CELLS WITH REDUCED VOLUME AND METHOD FOR THE PRODUCTION THEREOF | |
| DE102016200026B8 (de) | Wafer-Herstellungsverfahren | |
| EP3314245A4 (en) | BIOMOLECULAR SENSORS AND METHOD | |
| EP3352577A4 (en) | CANNABINOID COMPOSITIONS AND METHOD OF PREPARING THEREOF | |
| EP3365096A4 (en) | POLYMERMERMBRANE WITH OPEN PIPE HOLES AND METHOD FOR THE PRODUCTION THEREOF | |
| EP3378101A4 (en) | MULTILAYER PEROVSKITE, DEVICES AND METHOD FOR THE PRODUCTION THEREOF | |
| EP3357101A4 (en) | HETERO-TRANSITION PEROVSKIT PHOTOVOLTAIC MODULES AND METHOD FOR THE PRODUCTION THEREOF | |
| MA46474A (fr) | Formulations nanoparticulaires et leurs procédés de production et d'utilisation | |
| MA53939A (fr) | Compositions hémostatiques et leurs procédés de fabrication | |
| EP3370543A4 (en) | INSECT PRODUCTS AND METHOD FOR THE PRODUCTION THEREOF | |
| EP3347021A4 (en) | CYANOTHIENOTRIAZOLDIAZEPINE AND USES THEREOF | |
| MA51879A (fr) | Plaques de plâtre et leurs méthodes de fabrication | |
| EP3393292A4 (en) | FASTENING ARTICLES AND METHOD FOR THE PRODUCTION THEREOF | |
| EP3679607A4 (en) | ORGANIC-INORGANIC PEROVSKITE MATERIALS AND METHOD FOR THEIR PRODUCTION | |
| FR3033247B1 (fr) | Cages intervertebrales et leurs applications | |
| EP3538628A4 (en) | SYNTHETIC OLIGOMER COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF | |
| EP3375606A4 (en) | LAMINATE AND LAMINATE MANUFACTURING METHOD | |
| EP3433587A4 (en) | SCALE AND METHOD THEREFOR | |
| EP3360523A4 (en) | DEVICE AND METHOD FOR PRODUCING SHEET MATERIAL | |
| EP3448300A4 (en) | BIONIC IMPLANTS AND PRODUCTION PROCESSES THEREFOR |